Trump Administration’s New Policy on Fetal Tissue Research

Introduction to the Policy

The Trump administration announced Thursday that human fetal tissue derived from abortions can no longer be used in research funded by the National Institutes of Health. This policy, long urged by anti-abortion groups, expands restrictions issued during President Donald Trump’s first term. The government has funded research involving fetal tissue for decades, under both Republican and Democratic administrations.

Background on Fetal Tissue Use

The tissue, which otherwise would be thrown away, has been critical for certain research, including ways to fight HIV and cancer. Opponents of fetal tissue use say there are now alternatives, although many scientists say there aren’t always adequate substitutes.

By The Associated Press

Impact of the New Policy

In a statement Thursday, NIH Director Jay Bhattacharya acknowledged the agency “has long maintained policies governing the responsible and limited use of human fetal tissue in biomedical research.” Its use has declined since 2019. The $47 billion agency counted just 77 projects funded in 2024 that included fetal tissue. The first Trump administration ended the use of fetal tissue on NIH’s campus and set up additional hurdles for non-government scientists seeking NIH funding, restrictions that were subsequently lifted by the Biden administration. Thursday’s new policy covers all NIH-funded research.

Exceptions to the Policy

NIH documents say the policy doesn’t end the use of “cell lines” created years ago from fetal cells. Those are cloned copies of cells, such as embryonic stem cells, adapted to grow continuously in labs. Bhattacharya’s statement said NIH will soon seek comment about potential ways “to reduce or potentially replace reliance on human embryonic stem cells.”

Implications and Future Directions

The policy change has significant implications for medical research, particularly in areas where fetal tissue has been instrumental in advancing our understanding and treatment of diseases. The shift towards finding alternative methods and materials could lead to new discoveries but also poses challenges in terms of efficacy and ethical considerations.

Conclusion

The halt on the use of human fetal tissue in NIH-funded research marks a significant shift in the ethical and political landscape of medical research. While it aligns with the views of anti-abortion groups, it also raises concerns among scientists about the potential impact on critical research areas. The future of medical research will depend on the ability to adapt to these changes and find viable alternatives that do not compromise the advancement of health sciences.

FAQs

• Q: What is the new policy regarding human fetal tissue in research?
  • A: The Trump administration has announced that human fetal tissue derived from abortions can no longer be used in research funded by the National Institutes of Health.
• Q: Why has the use of fetal tissue been significant in research?
  • A: Fetal tissue has been critical for research into diseases like HIV and cancer, with many scientists arguing that there are not always adequate substitutes.
• Q: Are there any exceptions to the new policy?
  • A: Yes, the policy does not end the use of “cell lines” created years ago from fetal cells, which are cloned copies of cells adapted to grow continuously in labs.
• Q: How might this policy change affect medical research?
  • A: It could lead to new discoveries through the development of alternative methods but also poses challenges in terms of finding effective and ethical substitutes for fetal tissue.
• Q: What support does the AP Health and Science Department receive?
  • A: The AP Health and Science Department receives support from the Howard Hughes Medical Institute’s Science and Educational Media Group and the Robert Wood Johnson Foundation.